Next 10 |
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference PR Newswire STATEN ISLAND, N.Y. , May 2, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Compa...
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference PR Newswire STATEN ISLAND, N.Y. , April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the...
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Co...
Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in...
2024-03-19 10:23:08 ET More on Acurx Pharmaceuticals Acurx Sell-Off Presents Opportunity Before Upcoming Data Release Acurx stock plunges 26% amid Phase 2 data release for C. diff drug Read the full article on Seeking Alpha For further details see: Acurx ...
2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
2024-03-18 11:19:09 ET Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Conference Call March 18, 2024 08:00 AM ET Company Participants Robert Shawah - CFO David Luci - President and CEO Robert DeLuccia - Executive Chairman Conference Call Participants ...
2024-03-18 11:15:57 ET More on Acurx Pharmaceuticals Acurx Sell-Off Presents Opportunity Before Upcoming Data Release Acurx stock plunges 26% amid Phase 2 data release for C. diff drug ELAB, KIND and RLX among pre-market losers Seeking Alpha’s Quant Ra...
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clini...
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference PR Newswire STATEN ISLAND, N.Y. , May 2, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Compa...
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference PR Newswire STATEN ISLAND, N.Y. , April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the...
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Co...